Gri Bio, INC 8-K filings

GRI Bio announced that the U.S. FDA has granted Orphan Drug Designation to its investigational therapy GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

GRI Bio announced first quarter 2026 financial results, highlighting positive Phase 2a data for GRI-0621 in Idiopathic Pulmonary Fibrosis and progress on its pipeline.

GRI Bio reported full year 2025 financial results, a strengthened balance sheet with $8.2 million cash, and positive Phase 2a clinical data for its lead IPF program, GRI-0621.

GRI Bio announced additional positive Phase 2a clinical data for GRI-0621 in Idiopathic Pulmonary Fibrosis, demonstrating significant improvements in gene expression related to fibrosis and lung repair.

GRI Bio, Inc. announced a 1-for-28 reverse stock split to increase its per share trading price and regain Nasdaq listing compliance.

GRI Bio, Inc. announced it has conditionally regained compliance with Nasdaq's stockholders' equity requirement, avoiding potential delisting.

GRI Bio, Inc. stockholders approved a reverse stock split and the company believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement following an $8.0 million public offering.

GRI Bio, Inc. has increased its At The Market offering capacity to an aggregate of $7,379,813, allowing for further common stock sales.

GRI Bio announced additional positive Phase 2a clinical trial data for GRI-0621 in Idiopathic Pulmonary Fibrosis, reinforcing its disease-modifying mechanism, and confirmed its stockholders' equity exceeds Nasdaq's minimum requirement.

GRI Bio, Inc. announced the successful closing of its public offering, raising approximately $8.0 million in gross proceeds and exceeding $2.5 million in stockholders' equity.

GRI Bio, Inc. commenced a public offering expected to raise approximately $6.7 million to fund operations into late 2026.

GRI Bio, Inc. announced positive topline results from its Phase 2a clinical trial for GRI-0621 in idiopathic pulmonary fibrosis, demonstrating safety, tolerability, and disease-modifying potential.

GRI Bio, Inc. announced positive topline data from its Phase 2a clinical trial for GRI-0621 in Idiopathic Pulmonary Fibrosis, meeting its primary endpoint of safety and tolerability.

GRI BIO, Inc. received a notice from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement, potentially leading to delisting.

GRI Bio, Inc. reports positive interim Phase 2a data for GRI-0621 in Idiopathic Pulmonary Fibrosis and outlines plans for GRI-0803 in Systemic Lupus Erythematosus.

GRI Bio, Inc. stockholders approved an amendment to the company's 2018 Equity Incentive Plan, increasing the shares reserved for issuance by 400,000.

GRI Bio, Inc. announced positive 6-week interim biomarker data from its Phase 2a study of GRI-0621 for Idiopathic Pulmonary Fibrosis, with the Independent Data Monitoring Committee recommending the study continue due to no safety concerns.

GRI Bio, Inc. announced positive 6-week interim safety results for its lead drug candidate, GRI-0621, in an ongoing Phase 2a study for idiopathic pulmonary fibrosis (IPF), with the Independent Data Monitoring Committee recommending the study continue as planned due to no safety concerns.

GRI Bio, Inc. has increased the maximum number of shares available under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC to $1,758,934.

GRI Bio announces positive interim safety and biomarker results from its Phase 2a study of GRI-0621 for IPF, with topline data expected in Q3 2025 and cash runway through Q3 2025.

GRI Bio, Inc. has increased the maximum number of shares issuable under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC to $1,670,956.

GRI Bio, Inc. announces the dismissal of Sadler Gibb & Associates LLC and the appointment of WithumSmith+Brown, PC as its new independent registered public accounting firm.

GRI Bio announces the pricing of a $5.0 million public offering to fund the development of its Natural Killer T (NKT) cell modulator pipeline for inflammatory, fibrotic, and autoimmune diseases.

GRI Bio announced its full year 2024 financial results and reiterated its expectation for clinical data readouts in 2025 for its Phase 2a study of GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF).

GRI Bio, Inc. announced that it has regained compliance with Nasdaq's minimum bid price rule, as confirmed by a notification received on March 10, 2025.

GRI Bio, Inc. will implement a 1-for-17 reverse stock split of its common stock, effective February 21, 2025, to meet Nasdaq's minimum bid price requirement.

GRI Bio, Inc. stockholders approved a proposal to authorize a reverse stock split at a ratio between 1-for-2 and 1-for-23 at a Special Meeting held on February 11, 2025.

GRI Bio has increased the maximum number of shares it can issue under its At-The-Market Offering Agreement to $322,468, excluding shares already sold.

GRI Bio announced its third quarter 2024 financial results and provided an update on the progress of its lead program, GRI-0621, for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

GRI Bio has raised $13.9 million since the start of 2024, extending its cash runway into mid-Q1 2025 and supporting the development of its lead program for Idiopathic Pulmonary Fibrosis.